Peptides Research Hub

Clinical Trial Identifier

NCT04184622

Tirzepatide, part of the SURMOUNT program.

Trial details

Identifier
NCT04184622
Sponsor
Eli Lilly
Asset
Tirzepatide
Program
SURMOUNT
Phase
Phase III
Therapeutic area
Obesity / Weight Management

Program context

SURMOUNT

SURMOUNT-1 reported approximately 22.5% mean body-weight reduction at 72 weeks with tirzepatide 15 mg in adults with obesity without T2DM. SURMOUNT-2 demonstrated approximately 15.7% weight reduction in adults with T2DM and obesity. SURMOUNT-OSA showed significant reductions in apnea-hypopnea index supporting the obstructive sleep apnea indication.

Read the SURMOUNT spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.